Effexor (R) XR (venlafaxin HCI)
Company: Wyeth-Ayerst Laboratories
Approval Status: Approved October 1997
Treatment for: depression
Areas: Endocrinology; Psychiatry/Psychology
Possible similar drugs: Effexor
| General Information | Side Effects |
General Information
Wyeth-Ayerst Laboratories received marketing clearance from the U.S. Food and Drug Administration for Effexor (R) XR (venlafaxine HCI) Extended-Release Capsules. This is a once-a-day treatment that relieves the symptoms of depression. Clinical trial results also showed that patients receiving Effexor XR for the treatment of depression experienced a reduction in anxiety symptoms.
Side Effects
The most common side effects of Effexor included abnormal dreams, abnormal ejaculation, anorexia, dizziness, dry mouth, nausea, nervousness, somnolence, sweating and tremor.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
